Taking a closer look at Novavax (NVAX)
What’s up with Novavax?
Novavax(NVAX) opened at $20.02, which means the stock is down 10.39% from yesterday’s closing price of 20.54. Today, the company has a high of $20.30 and a low of $18.00. The stock holds a market cap of $948.65 million which is not impressive since the P/E ratio is -3.54. The company has a 52-week high of $26.34 and a 52-week low of $3.54.
What is P/E ratio?
The price-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of a company’s share price to the company’s earnings per share. The ratio is used for valuing companies and to find out whether they are overvalued or undervalued. Novavax has a weak.A negative PE ratio means that a stock has negative earnings. In other words, the company was losing money in the past 12 months.
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm’s vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.